SG Americas Securities LLC Invests $585,000 in OPKO Health, Inc. (NASDAQ:OPK)

SG Americas Securities LLC acquired a new position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 352,276 shares of the biotechnology company's stock, valued at approximately $585,000. SG Americas Securities LLC owned approximately 0.05% of OPKO Health at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of OPK. Ieq Capital LLC acquired a new stake in shares of OPKO Health during the fourth quarter worth approximately $52,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $102,000. Raymond James Financial Inc. acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $221,000. Essential Planning LLC. acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $506,000. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $91,000. Institutional investors and hedge funds own 64.63% of the company's stock.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost purchased 100,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were acquired at an average price of $1.65 per share, for a total transaction of $165,000.00. Following the purchase, the chief executive officer now owns 213,751,448 shares in the company, valued at approximately $352,689,889.20. This represents a 0.05% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have bought 500,000 shares of company stock worth $775,000 in the last ninety days. Insiders own 49.69% of the company's stock.

OPKO Health Price Performance

OPK stock remained flat at $1.29 during midday trading on Friday. 14,290,700 shares of the company's stock traded hands, compared to its average volume of 3,871,997. The company has a quick ratio of 2.28, a current ratio of 2.49 and a debt-to-equity ratio of 0.25. OPKO Health, Inc. has a 12-month low of $1.19 and a 12-month high of $2.04. The business has a fifty day moving average price of $1.35 and a two-hundred day moving average price of $1.52. The firm has a market cap of $1.02 billion, a PE ratio of -18.43 and a beta of 1.39.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The firm had revenue of $149.90 million for the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative return on equity of 2.85% and a negative net margin of 5.66%. The firm's revenue for the quarter was down 13.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.12) earnings per share. Equities analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on OPK. Barrington Research reaffirmed an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Thursday, May 1st. HC Wainwright reissued a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research report on Monday, April 7th. JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a research report on Friday, April 25th. They set a "neutral" rating on the stock. Finally, Wall Street Zen cut shares of OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, OPKO Health presently has a consensus rating of "Hold" and a consensus target price of $2.75.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.